Achieve Life Sciences, a specialty pharmaceutical company focused on cytisinicline for nicotine dependence, will present its first‑quarter 2026 financial results and host a conference call and webcast on May 12 at 8:30 AM EDT. The announcement was made on May 5, 2026.
The company’s Q1 2026 earnings are expected to be in‑line with prior guidance, as it remains pre‑revenue. Investors will see a continuation of the net loss trajectory, with Q1 2025 net loss of $12.8 million and Q4 2025 net loss of $14.7 million, underscoring the ongoing investment in clinical development and regulatory milestones.
Achieve’s business focus centers on cytisinicline, a novel nicotinic receptor partial agonist that has received FDA acceptance of its NDA for smoking cessation in September 2025 and a PDUFA date of June 20, 2026. The company also completed a Phase 2 study for vaping cessation and holds a Breakthrough Therapy designation for that indication.
Management has highlighted manufacturing challenges that delayed the NDA resubmission to Q4 2026 and pushed the projected commercial launch to the first half of 2027. In a March 24, 2026 press release, CEO Rick Stewart emphasized the company’s commitment to bringing cytisinicline to both smokers and vapers, noting that the product could transform nicotine dependence treatment.
The company’s cash position was $36.4 million at the end of 2025, raising concerns about near‑term funding. To address this, Achieve announced a private placement of up to $354 million in April 2026, which should extend runway and support ongoing development and eventual launch.
Investors will also learn about the company’s strategic partnership with Adare Pharma Solutions for U.S. manufacturing and a collaboration with Omnicom to develop a commercial launch strategy, positioning cytisinicline for a data‑driven market entry once regulatory approval is achieved.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.